Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Garon EB"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-10 z 10
    Tytuł:
    A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
    Autorzy:
    Garon EB
    Neidhart JD
    Gabrail NY
    de Oliveira MR
    Balkissoon J
    Kabbinavar F
    Pokaż więcej
    Temat:
    CA4P
    bevacizumab
    paclitaxel
    carboplatin
    NSCLC
    Neoplasms. Tumors. Oncology. Including cancer and carcinogens
    RC254-282
    Źródło:
    OncoTargets and Therapy, Vol Volume 9, Pp 7275-7283 (2016)
    Opis pliku:
    electronic resource
    Relacje:
    https://www.dovepress.com/a-randomized-phase-ii-trial-of-the-tumor-vascular-disrupting-agent-ca4-peer-reviewed-article-OTT; https://doaj.org/toc/1178-6930
    Dostęp URL:
    https://doaj.org/article/f01aed8737f74d1c9bacadfb0b27c314  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists.
    Autorzy:
    Mileham KF; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.
    Schenkel C; American Society of Clinical Oncology, Alexandria, Virginia, USA.
    Bruinooge SS; American Society of Clinical Oncology, Alexandria, Virginia, USA.
    Freeman-Daily J; The ROS1ders, Mountain View, California, USA.
    Basu Roy U; LUNGevity Foundation, Chicago, Illinois, USA.
    Moore A; LUNGevity Foundation, Chicago, Illinois, USA.
    Smith RA; American Cancer Society National Lung Cancer Roundtable, Atlanta, Georgia, USA.
    Garrett-Mayer E; American Society of Clinical Oncology, Alexandria, Virginia, USA.
    Rosenthal L; American Cancer Society National Lung Cancer Roundtable, Atlanta, Georgia, USA.
    Garon EB; University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA.
    Johnson BE; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
    Osarogiagbon RU; Baptist Cancer Center, Memphis, Tennessee, USA.
    Jalal S; Indiana University, Indianapolis, Indiana, USA.
    Virani S; Aurora Health Care, Burlington, Wisconsin, USA.
    Weber Redman M; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
    Silvestri GA; American Cancer Society National Lung Cancer Roundtable, Atlanta, Georgia, USA.
    Pokaż więcej
    Źródło:
    Cancer medicine [Cancer Med] 2022 Jan; Vol. 11 (2), pp. 530-538. Date of Electronic Publication: 2021 Dec 17.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Biomarkers, Tumor*
    Clinical Decision-Making*
    Oncologists*
    Carcinoma, Non-Small-Cell Lung/*diagnosis
    Lung Neoplasms/*diagnosis
    Carcinoma, Non-Small-Cell Lung/therapy ; Humans ; Lung Neoplasms/therapy ; Surveys and Questionnaires ; United States
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
    Autorzy:
    Dhar M; Department of Bioengineering, University of California, Los Angeles, California, USA.
    Wong J; Department of Bioengineering, University of California, Los Angeles, California, USA.
    Che J; Department of Bioengineering, University of California, Los Angeles, California, USA.; Vortex Biosciences Inc., Menlo Park, California, USA.
    Matsumoto M; Department of Bioengineering, University of California, Los Angeles, California, USA.
    Grogan T; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
    Elashoff D; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
    Garon EB; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.; Jonsson Comprehensive Cancer Center, California, USA.
    Goldman JW; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.; Jonsson Comprehensive Cancer Center, California, USA.
    Sollier Christen E; Vortex Biosciences Inc., Menlo Park, California, USA. .
    Di Carlo D; Department of Bioengineering, University of California, Los Angeles, California, USA. .; California NanoSystems Institute, California, USA. .; Jonsson Comprehensive Cancer Center, California, USA. .
    Kulkarni RP; Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. .; California NanoSystems Institute, California, USA. .; Jonsson Comprehensive Cancer Center, California, USA. .
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2018 Feb 07; Vol. 8 (1), pp. 2592. Date of Electronic Publication: 2018 Feb 07.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    B7-H1 Antigen/*metabolism
    Biomarkers, Tumor/*metabolism
    Carcinoma, Non-Small-Cell Lung/*secondary
    Lung Neoplasms/*pathology
    Neoplastic Cells, Circulating/*metabolism
    A549 Cells ; Adult ; Aged ; Aged, 80 and over ; Biopsy/methods ; Carcinoma, Non-Small-Cell Lung/therapy ; Female ; HeLa Cells ; Humans ; Immunotherapy ; Lung Neoplasms/therapy ; Male ; Middle Aged ; Neoplastic Cells, Circulating/drug effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
    Autorzy:
    Cummings AL; Department of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los Angeles 90095, USA.
    Garon EB; Department of Hematology and Oncology, David Geffen School of Medicine at the University of California, Los Angeles 90095, USA.
    Pokaż więcej
    Źródło:
    Cancer biology & medicine [Cancer Biol Med] 2017 Nov; Vol. 14 (4), pp. 341-347.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.
    Autorzy:
    Garon EB; Department of Medicine; Department of Hematology and Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA.
    Neidhart JD; San Juan Oncology Associates, Farmington, NM.
    Gabrail NY; Gabrail Cancer Center, Canton, OH.
    de Oliveira MR; Northwest Medical Specialties, Tacoma, WA.
    Balkissoon J; Global Product Development and Immuno-Oncology, PPD, Wilmington, NC, USA.
    Kabbinavar F; Department of Medicine; Department of Hematology and Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA.
    Pokaż więcej
    Źródło:
    OncoTargets and therapy [Onco Targets Ther] 2016 Nov 30; Vol. 9, pp. 7275-7283. Date of Electronic Publication: 2016 Nov 30 (Print Publication: 2016).
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Label-free enumeration, collection and downstream cytological and cytogenetic analysis of circulating tumor cells.
    Autorzy:
    Dhar M; Department of Bioengineering, University of California, 420 Westwood Plaza, 5121 Engineering V, P.O. Box 951600, Los Angeles, CA 90095, USA.
    Pao E; Department of Bioengineering, University of California, 420 Westwood Plaza, 5121 Engineering V, P.O. Box 951600, Los Angeles, CA 90095, USA.
    Renier C; Vortex Biosciences Inc., 1490 O'Brien Drive, Suite E, Menlo Park, CA 94025, USA.; Department of Surgery, Stanford University School of Medicine, MSLS Bldg, 1201 Welch Road, Stanford, CA 94305, USA.
    Go DE; Department of Bioengineering, University of California, 420 Westwood Plaza, 5121 Engineering V, P.O. Box 951600, Los Angeles, CA 90095, USA.
    Che J; Department of Bioengineering, University of California, 420 Westwood Plaza, 5121 Engineering V, P.O. Box 951600, Los Angeles, CA 90095, USA.; Vortex Biosciences Inc., 1490 O'Brien Drive, Suite E, Menlo Park, CA 94025, USA.
    Montoya R; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
    Conrad R; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
    Matsumoto M; Department of Bioengineering, University of California, 420 Westwood Plaza, 5121 Engineering V, P.O. Box 951600, Los Angeles, CA 90095, USA.
    Heirich K; Department of Surgery, Stanford University School of Medicine, MSLS Bldg, 1201 Welch Road, Stanford, CA 94305, USA.
    Triboulet M; Department of Surgery, Stanford University School of Medicine, MSLS Bldg, 1201 Welch Road, Stanford, CA 94305, USA.
    Rao J; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.
    Jeffrey SS; Department of Surgery, Stanford University School of Medicine, MSLS Bldg, 1201 Welch Road, Stanford, CA 94305, USA.
    Garon EB; Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.; UCLA Santa Monica Hematology Oncology, 2020 Santa Monica Blvd, Suite 600, Santa Monica, CA 90404, USA.
    Goldman J; Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.; UCLA Santa Monica Hematology Oncology, 2020 Santa Monica Blvd, Suite 600, Santa Monica, CA 90404, USA.
    Rao NP; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
    Kulkarni R; Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.; California NanoSystems Institute, 570 Westwood Plaza, Building 114, Los Angeles, CA 90095, USA.; Division of Dermatology, UCLA Medical Center, 52-121 CHS, Los Angeles, CA 90095, USA.
    Sollier-Christen E; Department of Bioengineering, University of California, 420 Westwood Plaza, 5121 Engineering V, P.O. Box 951600, Los Angeles, CA 90095, USA.; Vortex Biosciences Inc., 1490 O'Brien Drive, Suite E, Menlo Park, CA 94025, USA.; Department of Surgery, Stanford University School of Medicine, MSLS Bldg, 1201 Welch Road, Stanford, CA 94305, USA.
    Di Carlo D; Department of Bioengineering, University of California, 420 Westwood Plaza, 5121 Engineering V, P.O. Box 951600, Los Angeles, CA 90095, USA.; Vortex Biosciences Inc., 1490 O'Brien Drive, Suite E, Menlo Park, CA 94025, USA.; Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.; California NanoSystems Institute, 570 Westwood Plaza, Building 114, Los Angeles, CA 90095, USA.
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2016 Oct 14; Vol. 6, pp. 35474. Date of Electronic Publication: 2016 Oct 14.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Breast Neoplasms/*blood
    Carcinoma, Non-Small-Cell Lung/*blood
    Cell Separation/*methods
    Lung Neoplasms/*blood
    Microfluidics/*methods
    Neoplastic Cells, Circulating/*metabolism
    Anaplastic Lymphoma Kinase ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Case-Control Studies ; Cell Separation/instrumentation ; Female ; Humans ; In Situ Hybridization, Fluorescence/methods ; MCF-7 Cells ; Male ; Microfluidics/instrumentation ; Neoplastic Cells, Circulating/pathology ; Papanicolaou Test/methods ; Receptor Protein-Tyrosine Kinases/genetics ; Receptor Protein-Tyrosine Kinases/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
    Autorzy:
    Rizvi NA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY, 10065, USA. .
    Hellmann MD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY, 10065, USA.
    Snyder A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY, 10065, USA. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Kvistborg P; Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
    Makarov V; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Havel JJ; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Lee W; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Yuan J; Immune Monitoring Core, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Wong P; Immune Monitoring Core, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Ho TS; Immune Monitoring Core, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Miller ML; Computation Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Rekhtman N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Moreira AL; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Ibrahim F; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Bruggeman C; Department of Mathematics, Columbia University, New York, NY, 10027, USA.
    Gasmi B; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Zappasodi R; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Maeda Y; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Sander C; Computation Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Garon EB; David Geffen School of Medicine at UCLA, 2825 Santa Monica Boulevard, Suite 200, Santa Monica, CA 90404, USA.
    Merghoub T; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Wolchok JD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY, 10065, USA. Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Schumacher TN; Division of Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
    Chan TA; Weill Cornell Medical College, New York, NY, 10065, USA. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. .
    Pokaż więcej
    Źródło:
    Science (New York, N.Y.) [Science] 2015 Apr 03; Vol. 348 (6230), pp. 124-8. Date of Electronic Publication: 2015 Mar 12.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antibodies, Monoclonal, Humanized/*therapeutic use
    Antineoplastic Agents/*therapeutic use
    Carcinoma, Non-Small-Cell Lung/*drug therapy
    Carcinoma, Non-Small-Cell Lung/*genetics
    Drug Resistance, Neoplasm/*genetics
    Lung Neoplasms/*drug therapy
    Lung Neoplasms/*genetics
    Programmed Cell Death 1 Receptor/*antagonists & inhibitors
    CD8-Positive T-Lymphocytes/immunology ; Carcinoma, Non-Small-Cell Lung/immunology ; Cohort Studies ; DNA Repair/genetics ; Disease-Free Survival ; Humans ; Lung Neoplasms/immunology ; Mutation ; Smoking/genetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Uncertainty and psychological adjustment in patients with lung cancer.
    Autorzy:
    Kurita K; Department of Psychology, University of Southern California, Los Angeles, CA 90089-1061, USA.
    Garon EB
    Stanton AL
    Meyerowitz BE
    Pokaż więcej
    Źródło:
    Psycho-oncology [Psychooncology] 2013 Jun; Vol. 22 (6), pp. 1396-401. Date of Electronic Publication: 2012 Aug 13.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    Adaptation, Psychological*
    Emotions*
    Uncertainty*
    Depression/*etiology
    Lung Neoplasms/*psychology
    Adult ; Aged ; Aged, 80 and over ; California ; Cross-Sectional Studies ; Depression/diagnosis ; Depression/psychology ; Disease Progression ; Female ; Humans ; Lung Neoplasms/complications ; Male ; Middle Aged ; Perception ; Psychiatric Status Rating Scales ; Socioeconomic Factors ; Stress, Psychological/psychology ; Surveys and Questionnaires
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    High prevalence of lung cancer in a surgical cohort of lung cancer patients a decade after smoking cessation.
    Autorzy:
    Mong C; Division of Hematology Oncology, UCLA David Geffen School of Medicine, 200 UCLA Medical Plaza, Suite 420 Los Angeles, CA 90024 USA. />Garon EB
    Fuller C
    Mahtabifard A
    Mirocha J
    Mosenifar Z
    McKenna R
    Pokaż więcej
    Źródło:
    Journal of cardiothoracic surgery [J Cardiothorac Surg] 2011 Feb 25; Vol. 6, pp. 19. Date of Electronic Publication: 2011 Feb 25.
    Typ publikacji:
    Comparative Study; Journal Article
    MeSH Terms:
    Pneumonectomy*
    Lung Neoplasms/*epidemiology
    Smoking/*adverse effects
    Smoking Cessation/*statistics & numerical data
    Aged ; California/epidemiology ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/surgery ; Male ; Prevalence ; Prognosis ; Retrospective Studies ; Risk Factors ; Time Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-10 z 10

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies